Hope Rugo, Professor of Medicine and Director of the Breast Oncology Clinical Trials Program at the University of California at San Francisco, shared Sarah Sammons’s, newly appointed Co-Leader of Breast Oncology at UMGCCC and former Senior Physician at Dana-Farber, post on X, adding:
“Fabulous approval – an important step in improving outcome for mTNBC. Important! This table is misleading as missing the xover major differences between the trials which have a big impact on OS. Why is the ORR so low in the control arm of TB02? Major caution in xtrial comparisons.”
Quoting Sarah Sammons’s post:
“FDA approves Dato-DXd (Datroway) for 1L metastatic TNBC in patients ineligible for immunotherapy (70% of pts). Now we have 2 TROP2 ADCs in same indication; we can only use 1 upfront.
TROPION-Breast02 vs ASCENT-03:
- Similar PFS (10.8 vs 9.7 mo), OS (23.7 vs 21.5 mo), and DOR (12.3 vs 12.2 mo).
Dato-DXd showed higher ORR (62.5% vs 48%), a very different side effect profile (stomatitis/dry eye vs neutropenia/diarrhea), Q3W vs days 1+8 dosing.
Nice brain metastases activity with Dato-DXd; HR of 0.3 in the brain mets subgroup. DFI pts <6 months only included in Dato-DXd trial.
For IO-ineligible mTNBC, we have two nice options.”
Other articles featuring Hope Rugo and Sarah Sammons on OncoDaily.